CTLA4 and neoplasm: Thus, uncovering other predictive biomarkers for immune blockade responses—such as CTLA-4/PD-1 expression on immune infiltrate and tumor cells, TILs, and circulating MDSCs and lymphocytes—should be prioritized in order to improve the efficacy of personalized treatments of patient (215, 216).